NEW YORK, February 24, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Moments ago, Analysts Review released new research updates concerning several important developing situations including IRIDEX (NASDAQ: IRIX), Masimo (NASDAQ: MASI), Natus Medical (NASDAQ: BABY), Vision-Sciences (NASDAQ:VSCI), and Novadaq (NASDAQ: NVDQ). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA(R) research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

IRIX Research Report: ( http://get.analystsreview.com/pdf/?c=IRIDEX&d=24-Feb-2015&s=IRIX ),

MASIResearch Report: ( http://get.analystsreview.com/pdf/?c=Masimo&d=24-Feb-2015&s=MASI ),

BABY Research Report: ( http://get.analystsreview.com/pdf/?c=Natus%20Medical&d=24-Feb-2015&s=BABY ),

VSCI Research Report: ( http://get.analystsreview.com/pdf/?c=Vision-Sciences&d=24-Feb-2015&s=VSCI ),

NVDQ Research Report: ( http://get.analystsreview.com/pdf/?c=Novadaq&d=24-Feb-2015&s=NVDQ ).

============

--

Analyst Update: FDA Clearance, Technology Installation, Financial Outlook, Upcoming Events

Reviewed by: Rohit Tuli, CFA(R)

U.S. stock markets witnessed a mixed trend on Monday, as the indices pulled back from records reached last week. The Dow Jones Industrial Average fell 23.6 points, or 0.1%, to 18116.84. The S&P 500 lost 0.64 point to 2109.66, while the Nasdaq Composite added 5.01 points, or 0.1%, to 4960.97. Falling oil prices and disappointing data on US existing home sales weighed upon the markets. However, European stocks rallied after Greek creditors agreed to extend the nation's bailout funds. The Stoxx Europe 600 Index added 0.7% to 385.08 at the close in London. Asian markets were mostly up on Monday, buoyed by a bailout deal between Greece and the euro zone last week. Japan's key Nikkei 225 index jumped 0.7% and Australia's benchmark S&P ASX 200 index gained 0.5%. Trading volumes remained light with China, Taiwan and Vietnam still closed for the Chinese New Year holiday.

IRIDEX Corporation (IRIDEX) announced the receipt of FDA clearance for the marketing of its first laser system - Cyclo G6 Laser System, designed solely for use in treating glaucoma and its symptoms. The 510(k) clearance allows the Company to initially sell the IRIDEX Cyclo G6 Laser System with two disposable delivery probes, the MicroPulse P3TM probe and the G-ProbeTM.

Masimo Corporation (Masimo) announced the installation of Masimo Patient SafetyNet(TM), which is a remote monitoring and clinician notification system to keep patients safer while reducing cost of care, at Inova Fair Oaks Hospital. The installation of Patient SafetyNet aims to reduce preventable and costly rescue events, transfers to intensive care units, and deaths related to opioid-induced respiratory depression.

Natus Medical Incorporated's (Natus Medical) Sr. Vice-President and CFO, Jonathan Kennedy is scheduled to make a presentation at the Raymond James 36th Annual Institutional Investors Conference in Orlando, Florida on Monday, March 2, 2015 at 10:30 a.m. The Company has also recently raised its financial guidance for 2015.

In the first week of February, Vision-Sciences, Inc. (Vision) announced its financial results for the third quarter of FY 2015. Net sales increased 9% YoY to $4.9 million driven by higher sales in medical and industrial businesses. Medical sales of $3.9 million for the third quarter of FY 2015 increased 8% YoY, while Industrial sales increased 16% YoY to $1.1 million.

Novadaq Technologies Inc (Novadaq) is scheduled to participate at RBC Capital Markets' 2015 Global Healthcare Conference on February 24, 2015 in New York. The Company intends to release its Q4 2014 and full year 2014 financial results on February 25, 2015. For 2014, the Company anticipates total revenues of approximately $46.6 million, up by around 33%.

--

About Analysts Review

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA(R). An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Analysts Review